Innoviva (INVA) EBIT (QoQ) (2010 - 2026)
Powered by 
Analysis
Innoviva (INVA) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.29% |
| Mar 31, 2026 | 376.02% |
| Dec 31, 2025 | -111.08% |
| Sep 30, 2025 | 155.91% |
| Jun 30, 2025 | 17.68% |
| Mar 31, 2025 | 493.09% |
| Dec 31, 2024 | -108.52% |
| Sep 30, 2024 | 126.25% |
| Jun 30, 2024 | 111.92% |
| Mar 31, 2024 | 492.29% |
| Dec 31, 2023 | -106.27% |
| Sep 30, 2023 | 435.39% |
| Jun 30, 2023 | -44.43% |
| Mar 31, 2023 | -109.86% |
| Dec 31, 2022 | -114.41% |
| Sep 30, 2022 | -13.15% |
| Jun 30, 2022 | 6.21% |
| Mar 31, 2022 | 1,385.20% |
| Dec 31, 2021 | -102.24% |
| Sep 30, 2021 | 180.27% |